Related Experiment Video
Updated: Jun 16, 2026

Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry
Published on: July 17, 2017
Podocyte-specific expression of tamoxifen-inducible Cre recombinase in mice
Hideki Yokoi1, Masato Kasahara, Masashi Mukoyama
1Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.
Background:
Podocytes play an important role in maintaining normal glomerular function. A podocyte-specific conditional knockout technology has been established by the use of transgenic mice expressing a podocyte-specific Cre recombinase to clarify the role of genes expressed in the podocytes. However, it may be difficult to examine the role of genes in certain pathologic conditions using conventional podocyte-specific knockout mice because they may be embryonically lethal or exhibit congenital renal abnormality.
Methods:
To introduce a temporal control in the genetic experiments targeting the podocyte, we constructed tamoxifen-inducible Cre recombinase (CreER(T2)) transgenic mice under the control of podocyte-specific promoter, 2.5-kb fragment of the human podocin (NPHS2) gene. The specificity and efficiency of Cre activity were examined by crossing NPHS2-CreER(T2) with the ROSA26 reporter (R26R) mouse in which a floxed-stop cassette has been placed upstream of the beta-galactosidase gene. Four-week-old double-mutant mice (NPHS2-CreER(T2)/R26R) were intraperitoneally administered with 0.5 mg of 4-hydroxytamoxifen (4-OHT) for three consecutive days.
Results:
NPHS2-CreER(T2)/R26R treated with 4-OHT expressed beta-galactosidase specifically in 85% of the podocytes in glomeruli. Expression of Cre recombinase mRNA was mostly restricted to the kidney, especially in glomeruli.
Conclusions:
In conclusion, we have successfully generated podocyte-specific inducible Cre transgenic mice by tamoxifen administration. These mice allow us to disrupt the genes specifically in the podocytes after birth.
Insights
Researchers developed new inducible transgenic mice for studying podocyte gene function. This tamoxifen-inducible system allows gene disruption in podocytes after birth, overcoming limitations of earlier models.
Area of Science:
- Nephrology
- Genetics
- Molecular Biology
Background:
- Podocytes are crucial for normal kidney glomerular function.
- Existing podocyte-specific knockout mice have limitations for studying gene function in certain disease states.
- Embryonic lethality or congenital abnormalities can hinder research with conventional models.
Purpose of the Study:
- To develop a temporal control system for genetic manipulation in podocytes.
- To create tamoxifen-inducible Cre recombinase transgenic mice for podocyte research.
- To enable gene disruption in podocytes post-birth.
Main Methods:
- Constructed NPHS2-CreER(T2) transgenic mice using a podocin promoter.
- Crossed NPHS2-CreER(T2) mice with ROSA26 reporter mice to assess Cre activity.
- Administered tamoxifen (4-OHT) to 4-week-old double-mutant mice.
Main Results:
- Tamoxifen administration resulted in beta-galactosidase expression specifically in 85% of glomerular podocytes.
- Cre recombinase mRNA expression was predominantly localized to the kidney, particularly glomeruli.
- Demonstrated successful temporal and podocyte-specific gene targeting.
Conclusions:
- Successfully generated podocyte-specific inducible Cre transgenic mice.
- Tamoxifen administration enables targeted gene disruption in adult podocytes.
- These mice are valuable tools for investigating podocyte gene function in various conditions.
Related Concept Videos
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
In-vitro Mutagenesis

